Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25^th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 11, 2023 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 11 - 13, 2023.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

CONTACT:  

Monopar Therapeutics Inc.
Investor Relations  
Kim R. Tsuchimoto  
Chief Financial Officer  
[email protected]

Follow Monopar on social media for updates: 
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

You May Also Be Interested In

• Two Weeks After Open-Sourcing ZSvirt, Five-Minute Trial Images Arrive as GitHub Stars Pass 1.4K
• Levicept Announces Attendance at Cantor and Jefferies Global Healthcare Conferences
• Semicon Network Summit 2026 Advances Global Chip Collaboration in the AI Era